Takeda Pharmaceutical (NYSE:TAK) Hits New 1-Year High – Should You Buy?

Takeda Pharmaceutical Co. (NYSE:TAK – Get Free Report)’s share price reached a new 52-week high during trading on Monday. The company traded as high as $21.75 and last traded at $21.7980, with a volume of 8,578 shares changing hands. The stock had previously closed at $21.43.

Analyst Ratings Changes

TAK has been the topic of a number of recent research reports. Weiss Ratings raised Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, November 3rd. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. Finally, Wall Street Zen lowered shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Buy”.

View Our Latest Stock Analysis on TAK

Takeda Pharmaceutical Stock Performance

The business’s 50-day moving average price is $19.40 and its 200-day moving average price is $17.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.60 and a current ratio of 1.15. The stock has a market cap of $69.65 billion, a P/E ratio of 28.57 and a beta of -0.02.

Insider Buying and Selling

In other Takeda Pharmaceutical news, insider Andrew Plump sold 116,191 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the completion of the sale, the insider owned 145,465 shares of the company’s stock, valued at approximately $2,689,647.85. The trade was a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deidre Greenway sold 12,980 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total value of $235,067.80. Following the completion of the sale, the insider owned 40,049 shares of the company’s stock, valued at approximately $725,287.39. The trade was a 24.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 238,974 shares of company stock valued at $4,549,461 in the last 90 days. 0.04% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TAK. Renaissance Technologies LLC increased its stake in Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after acquiring an additional 370,800 shares during the last quarter. Quantinno Capital Management LP boosted its position in shares of Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after acquiring an additional 219,999 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after acquiring an additional 60,725 shares during the last quarter. Bleakley Financial Group LLC grew its holdings in shares of Takeda Pharmaceutical by 2.8% in the third quarter. Bleakley Financial Group LLC now owns 444,988 shares of the company’s stock valued at $8,094,000 after purchasing an additional 12,032 shares in the last quarter. Finally, Ethic Inc. grew its holdings in shares of Takeda Pharmaceutical by 19.5% in the third quarter. Ethic Inc. now owns 436,514 shares of the company’s stock valued at $7,940,000 after purchasing an additional 71,261 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

About Takeda Pharmaceutical

(Get Free Report)

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Further Reading

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.